ArticleLife (Basel, Switzerland)2026
Hidden Gut Dysbiosis in Apparently Healthy Adults.
Article in Life (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
(1) Background: Intestinal dysbiosis has been implicated in numerous gastrointestinal, metabolic, and immune-mediated disorders; however, data regarding its prevalence in asymptomatic adults remain limited. This study evaluated the prevalence and integrated profile of microbiological, functional, and immunological alterations associated with dysbiosis in apparently healthy adults undergoing intestinal microbiota screening. (2) Methods: A laboratory-based cross-sectional study included 98 asymptomatic adults. In the present study, intestinal dysbiosis was defined as a multidimensional laboratory phenotype reflecting disruption of intestinal microbial, fungal, metabolic, luminal, or mucosal immune homeostasis. Bacterial and fungal markers, short-chain fatty acids (SCFAs), fecal pH, and mucosal immune biomarkers were assessed and grouped into predefined biological domains. Dysbiosis complexity was evaluated according to the number of affected domains. (3) Results: At least one laboratory abnormality was identified in 97 participants (99.0%), while 54 (55.1%) exhibited alterations in three or more biological domains. Core bacterial imbalance was detected in 87 (88.8%) participants, inflammatory and mucosal immune abnormalities in 85 (86.7%), opportunistic bacterial overgrowth in 61 (62.2%), depletion of protective bacteria in 58 (59.2%), and fungal overgrowth in 49 (50.0%). Reduced SCFA markers were observed in 27 (27.6%) participants and altered fecal pH in 33 (33.7%). Correlation analysis revealed clustering of SCFA markers and biologically plausible associations between microbial and mucosal immune biomarkers. (4) Conclusions: Laboratory abnormalities related to intestinal dysbiosis were highly prevalent and predominantly occurred as multidomain profiles, supporting dysbiosis as a complex biological phenotype requiring integrated microbiological, metabolic, and immunological assessment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.